NCT06416865 - Efficacy and Safety of AJU-C52 in Essential Hypertension Patients | Biotech Hunter

Enrollment

190

Participants

Timeline

Start Date

June 27, 2022

Primary Completion Date

December 12, 2022

Study Completion Date

August 31, 2024

Conditions

Essential Hypertension

Interventions

DRUG

AJU-C52L, AJU-C52

"AJU-C52L+C52R1L placebo: Subjects take the investigational products once a day for 2 weeks.~AJU-C52+C52R1M placebo: Subjects take the investigational products once a day for 6 weeks."

DRUG

C52R1L, C52R1M

"C52R1L+AJU-C52L placebo: Subjects take the investigational products once a day for 2 weeks.~C52R1M+AJU-C52 placebo: Subjects take the investigational products once a day for 6 weeks."

Trial Locations (1)

Unknown

RECRUITING

AJU Pharm Co., Ltd., Seoul

All Listed Sponsors

lead

AJU Pharm Co., Ltd.

INDUSTRY